According to the latest announcement on the website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), Eli Lilly and Co.'s blockbuster drug GIP/GLP-1 receptor dual agonist Tirzepatide injection has obtained acceptance for the application for a new indication, and the specific indication has not been disclosed. According to the official website of the CDE, this is the third application for market approval of Tirzepatide submitted in China.

Public information shows that Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, administered once a week. The product was approved by the FDA in May 2022 and November 2023 for the treatment of diabetes, obesity, and overweight patients. In China, Tirzepatide obtained its first indication approval in May this year for blood sugar control in adults with type 2 diabetes. In July this year, the product was approved by the National Medical Products Administration (NMPA) again for long-term weight management in overweight patients with at least one weight-related comorbidity.